AstraZeneca/Daiichi Sankyo’s Next ADC Shows Promise In Triple-Negative Breast Cancer

Aiming To Overhaul Gilead’s Trodelvy

AstraZeneca
AstraZeneca and Daiichi Sankyo are looking to repeat the success seen with Enhertu • Source: Shutterstock: Elzbieta Krzysztof

More from Anticancer

More from Therapeutic Category